Cartesian Therapeutics grants stock options to five new employees as hiring incentive.

Cartesian Therapeutics, a biotech company specializing in cell therapy for autoimmune diseases, granted inducement stock options to five new employees on May 1, 2026. The options total 317,200 shares at an exercise price of $6.22, vesting over four years with a ten-year term. This move aims to attract talent as the company advances its lead CAR-T therapy, Descartes-08, through multiple clinical trials for autoimmune conditions. The grants were approved by the board and comply with Nasdaq rules for employment inducements.